Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 571 to 585 of 1553 results for do not do recommendations

  1. Suspected neurological conditions: recognition and referral (QS198)

    This quality standard covers assessing and referring children (under 16) and adults (16 and over) who have symptoms or signs associated with neurological conditions. It describes high-quality care in priority areas for improvement.

  2. Transient loss of consciousness ('blackouts') in over 16s (QS71)

    This quality standard covers assessing, diagnosing and referring people (aged 16 and over) who have had a transient loss of consciousness (often called a blackout). It describes high-quality care in priority areas for improvement.

  3. People and communities - putting you at the heart of our work

    NICE is committed to involving people who use services, carers and the public in the development of our guidance and other products.

  4. People and communities - putting you at the heart of our work

    NICE is committed to involving people who use services, carers and the public in the development of our guidance and other products.

  5. Fetal alcohol spectrum disorder (QS204)

    This quality standard covers assessing and diagnosing fetal alcohol spectrum disorder (FASD) in children and young people. It also covers support during pregnancy to prevent FASD. It describes high-quality care in priority areas for improvement.

  6. Percutaneous insertion of a closure device to repair a paravalvular leak around a replaced mitral or aortic valve (IPG700)

    Evidence-based recommendations on percutaneous insertion of a closure device to repair a paravalvular leak around a replaced mitral or aortic valve. This involves passing a closure device through a catheter to block the area that is leaking.

  7. Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (TA496)

    Evidence-based recommendations on ribociclib (Kisqali) as initial endocrine-based therapy for hormone-receptor positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic (secondary) breast cancer in adults.

  8. Relugolix–estradiol–norethisterone for treating symptoms of endometriosis (TA1057)

    Evidence-based recommendations on relugolix–estradiol–norethisterone (Ryeqo) for treating symptoms of endometriosis in adults of reproductive age.

  9. Acute upper gastrointestinal bleeding in adults (QS38)

    This quality standard covers the management of acute upper gastrointestinal bleeding in adults and young people (aged 16 and over). It describes high-quality care in priority areas for improvement.

  10. Care of dying adults in the last days of life (QS144)

    This quality standard covers the clinical care of adults (aged 18 and over) who are dying, during the last 2 to 3 days of life. It describes high-quality care in priority areas for improvement.

  11. Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer (TA951)

    Evidence-based recommendations on olaparib (Lynparza) with abiraterone for untreated hormone-relapsed metastatic prostate cancer in adults.

  12. Orforglipron for treating type 2 diabetes [TSID12130]

    Topic prioritisation

  13. Robot-assisted kidney transplant (IPG609)

    Evidence-based recommendations on robot-assisted kidney transplant in adults. This involves the surgeon using a robot to help with a kidney transplant.

  14. Durvalumab with etoposide and either carboplatin or cisplatin for untreated extensive-stage small-cell lung cancer (TA1041)

    Evidence-based recommendations on durvalumab (Imfinzi) with etoposide and either carboplatin or cisplatin for untreated extensive-stage small-cell lung cancer in adults.